Independent Director Director Since: 2024 Age: 70 Committee Service: Compensation Science and Technology Professional Experience: President and Chief Executive Officer, Kronos Bio, Inc. (2018 2024) Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences, Inc. (2007 2018), and preceded by various positions of increasing responsibility (1990 2007) Senior Scientist, DNA Synthesis Group, Genentech, Inc. (1986 1990) Education: Ph.D., Organic Chemistry, Eidgen ssische Technische Hochschule Other Public Company Boards: Kronos Bio, Inc. (2018 2025) Morphic Therapeutic Inc. (2019 2024) Bayer AG (2017 2024) Other Affiliations: Service on the boards of directors for private biotechnology companies, including: MiNA Therapeutics Limited; and Rezo Therapeutics, Inc. Research in organic chemistry and applied enzymology in Professor George Whiteside s lab at Harvard University, Cambridge, Massachusetts Fellow of The American Association for Advancement of Science The Nominating and Corporate Governance Committee and Board believe Dr. Bischofberger is qualified to serve on the Board due to his mid-to-late-stage clinical development and scientific expertise and his experience as Chief Executive Officer and a director of publicly traded companies.